239 related articles for article (PubMed ID: 33750896)
1. Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A.
Boutary S; Caillaud M; El Madani M; Vallat JM; Loisel-Duwattez J; Rouyer A; Richard L; Gracia C; Urbinati G; Desmaële D; Echaniz-Laguna A; Adams D; Couvreur P; Schumacher M; Massaad C; Massaad-Massade L
Commun Biol; 2021 Mar; 4(1):317. PubMed ID: 33750896
[TBL] [Abstract][Full Text] [Related]
2. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
[TBL] [Abstract][Full Text] [Related]
3. Tead1 regulates the expression of Peripheral Myelin Protein 22 during Schwann cell development.
Lopez-Anido C; Poitelon Y; Gopinath C; Moran JJ; Ma KH; Law WD; Antonellis A; Feltri ML; Svaren J
Hum Mol Genet; 2016 Jul; 25(14):3055-3069. PubMed ID: 27288457
[TBL] [Abstract][Full Text] [Related]
4. The alpha-chemokine CXCL14 is up-regulated in the sciatic nerve of a mouse model of Charcot-Marie-Tooth disease type 1A and alters myelin gene expression in cultured Schwann cells.
Barbaria EM; Kohl B; Buhren BA; Hasenpusch-Theil K; Kruse F; Küry P; Martini R; Müller HW
Neurobiol Dis; 2009 Mar; 33(3):448-58. PubMed ID: 19111616
[TBL] [Abstract][Full Text] [Related]
5. Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice.
Lee JS; Lee JY; Song DW; Bae HS; Doo HM; Yu HS; Lee KJ; Kim HK; Hwang H; Kwak G; Kim D; Kim S; Hong YB; Lee JM; Choi BO
Nucleic Acids Res; 2020 Jan; 48(1):130-140. PubMed ID: 31713617
[TBL] [Abstract][Full Text] [Related]
6. A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice.
Stavrou M; Kagiava A; Choudury SG; Jennings MJ; Wallace LM; Fowler AM; Heslegrave A; Richter J; Tryfonos C; Christodoulou C; Zetterberg H; Horvath R; Harper SQ; Kleopa KA
J Clin Invest; 2022 Jul; 132(13):. PubMed ID: 35579942
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the PMP22 gene through an intronic enhancer.
Jones EA; Lopez-Anido C; Srinivasan R; Krueger C; Chang LW; Nagarajan R; Svaren J
J Neurosci; 2011 Mar; 31(11):4242-50. PubMed ID: 21411665
[TBL] [Abstract][Full Text] [Related]
8. Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease.
Niemann A; Berger P; Suter U
Neuromolecular Med; 2006; 8(1-2):217-42. PubMed ID: 16775378
[TBL] [Abstract][Full Text] [Related]
9. Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression.
Fortun J; Go JC; Li J; Amici SA; Dunn WA; Notterpek L
Neurobiol Dis; 2006 Apr; 22(1):153-64. PubMed ID: 16326107
[TBL] [Abstract][Full Text] [Related]
10. AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A.
Gautier B; Hajjar H; Soares S; Berthelot J; Deck M; Abbou S; Campbell G; Ceprian M; Gonzalez S; Fovet CM; Schütza V; Jouvenel A; Rivat C; Zerah M; François V; Le Guiner C; Aubourg P; Fledrich R; Tricaud N
Nat Commun; 2021 Apr; 12(1):2356. PubMed ID: 33883545
[TBL] [Abstract][Full Text] [Related]
11. Molecular genetics of autosomal-dominant demyelinating Charcot-Marie-Tooth disease.
Houlden H; Reilly MM
Neuromolecular Med; 2006; 8(1-2):43-62. PubMed ID: 16775366
[TBL] [Abstract][Full Text] [Related]
12. Evidence for impaired axonal regeneration in PMP22 duplication: studies in nerve xenografts.
Sahenk Z; Serrano-Munuera C; Chen L; Kakabadze I; Najagara HN
J Peripher Nerv Syst; 2003 Jun; 8(2):116-27. PubMed ID: 12795716
[TBL] [Abstract][Full Text] [Related]
13. Proliferation of Schwann cells and regulation of cyclin D1 expression in an animal model of Charcot-Marie-Tooth disease type 1A.
Atanasoski S; Scherer SS; Nave KA; Suter U
J Neurosci Res; 2002 Feb; 67(4):443-9. PubMed ID: 11835311
[TBL] [Abstract][Full Text] [Related]
14. Pmp22 mutant allele-specific siRNA alleviates demyelinating neuropathic phenotype in vivo.
Lee JS; Chang EH; Koo OJ; Jwa DH; Mo WM; Kwak G; Moon HW; Park HT; Hong YB; Choi BO
Neurobiol Dis; 2017 Apr; 100():99-107. PubMed ID: 28108290
[TBL] [Abstract][Full Text] [Related]
15. Animal models of Charcot-Marie-Tooth disease type 1A.
Sereda MW; Nave KA
Neuromolecular Med; 2006; 8(1-2):205-16. PubMed ID: 16775377
[TBL] [Abstract][Full Text] [Related]
16. Electroceutical approach ameliorates intracellular PMP22 aggregation and promotes pro-myelinating pathways in a CMT1A in vitro model.
Intisar A; Woo H; Kang HG; Kim WH; Shin HY; Kim MY; Kim YS; Mo YJ; Lee YI; Kim MS
Biosens Bioelectron; 2023 Mar; 224():115055. PubMed ID: 36630746
[TBL] [Abstract][Full Text] [Related]
17. Expression of myelin proteins in the adult heterozygous Trembler mouse.
Vallat JM; Sindou P; Garbay B; Preux PM; Anani T; Richard L; Diot M
Acta Neuropathol; 1999 Sep; 98(3):281-7. PubMed ID: 10483786
[TBL] [Abstract][Full Text] [Related]
18. Inherited demyelinating neuropathies with micromutations of peripheral myelin protein 22 gene.
Taioli F; Cabrini I; Cavallaro T; Acler M; Fabrizi GM
Brain; 2011 Feb; 134(Pt 2):608-17. PubMed ID: 21252112
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A.
Robertson AM; Perea J; McGuigan A; King RH; Muddle JR; Gabreëls-Festen AA; Thomas PK; Huxley C
J Anat; 2002 Apr; 200(4):377-90. PubMed ID: 12090404
[TBL] [Abstract][Full Text] [Related]
20. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
